Patrick co-leads Frazier’s Life Sciences team and invests across the spectrum of therapeutics opportunities, from early-stage clinical development companies to commercial-stage pharmaceutical companies.
Patrick is a Managing Partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Throughout his 16 years as a Managing Partner, Patrick has led or co-led investments across 30 companies.
Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage anti-infectives companies to >$100M commercial-stage dermatology companies. Patrick has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), Silvergate Pharmaceuticals (acquired by CutisPharma), Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of Arcutis Biotherapeutics (NASDAQ: ARQT), Imago BioSciences, Iterum Therapeutics (NASDAQ: ITRM), MBX Biosciences, Mirum Pharmaceuticals (NASDAQ: MIRM), Passage Bio (NASDAQ: PASG), Scout Bio, and Vaxcyte (NASDAQ: PCVX). He is also a board observer for Aspen Neuroscience.
Prior to joining Frazier, Patrick helped develop McKinsey & Company's West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.
Patrick received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.
University of North Carolina at Chapel Hill (B.A.)
Harvard University (M.B.A.)